Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
Arun Danewa, Senior Consultant at Artemis Hospitals, shared a post on LinkedIn:
“The Blood Vessel Mystery: Saving a Bone Marrow Patient
Think of a Bone Marrow Transplant (BMT) as a total system restart. It’s a lifesaving process, but sometimes the ‘new system’ hits a dangerous glitch.
In this case, a patient recovering from severe aplastic anemia survived a massive infection (MDR Sepsis) only to face a new, hidden enemy:
Transplant Associated Thrombotic microangiopathy (TA-TMA).
The Red Flags
How do you know when something is wrong?
The body starts sending ‘SOS’ signals.
For our patient, those signals were:
- High Blood Pressure: The heart was working too hard.
- Protein in Urine: A sign the kidneys were struggling.
- Crushed Red Cells: Under the microscope, we saw Schistocytes—red blood cells that looked like they’d been shattered.
These ‘alarm bells’ pointed to TA-TMA, a condition where tiny blood clots start forming in the small vessels, damaging organs.
The Rescue Plan
To fix this, we had to act like detectives and change our strategy fast:
- Stop the ‘Trigger’: We realized a specific medicine the patient was taking to prevent transplant rejection (Cyclosporine) was actually causing the damage. We stopped it immediately.
- Switch the Shield: To keep the patient safe from rejection, we switched them to Steroids instead.
- Double-Check the Enemy: We ran a special test (ADAMTS13) to make sure this wasn’t a different, rarer blood disorder. The test confirmed we were on the right track.
The Result: A Huge Comeback
In just 11 days, the patient’s body began to heal. The ‘stress’ markers in their blood dropped, and their healthy cell counts climbed back up.
The Lesson
In transplant medicine, watching closely saves lives. By catching high blood pressure and kidney changes early, we can stop a major complication before it does permanent damage. It’s all about knowing when to change the plan to fit the patient’s needs.”
Stay updated with Hemostasis Today.
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis